18889881171
Kalkine 0
countryflagUS

ARCA Biopharma Inc

Healthcare US ABIO

NoneUSD
-(-%)

Last update at 2024-09-30T06:06:49.942053Z

Day Range

--
LowHigh

52 Week Range

1.564.49
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap51.50M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-7.96800M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.42

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -9.92600M -19.32200M -9.74700M -5.64900M -7.96400M
Minority interest - - - - -
Net income -9.25600M -19.23100M -9.73800M -5.48200M -7.93100M
Selling general administrative 5.85M 5.50M 4.77M 3.98M 3.88M
Selling and marketing expenses - - - - -
Gross profit - - - - 0.00000M
Reconciled depreciation 0.11M 0.09M 0.09M 0.09M 0.02M
Ebit -10.71000M -19.33500M -9.76600M -5.81400M -7.95600M
Ebitda -10.59600M -19.32200M -9.73800M -5.55300M -7.93400M
Depreciation and amortization 0.11M 0.01M 0.03M 0.26M 0.02M
Non operating income net other - - 0.03M 0.17M 0.16M
Operating income -10.59600M -19.33500M -9.76600M -5.81400M -8.11800M
Other operating expenses 10.60M 19.34M 9.77M 5.81M 8.12M
Interest expense 0.68M 0.01M 0.00900M 0.00700M 0.00800M
Tax provision - 0.00000M -0.00900M -0.16700M -0.03100M
Interest income 0.68M 0.01M 0.03M 0.17M 0.16M
Net interest income 0.68M 0.01M 0.02M 0.17M 0.15M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.67000M -0.09100M -0.00900M -0.16700M -0.03100M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 10.60M 19.34M 9.77M 5.81M 8.12M
Cost of revenue - - - - 0.00000M
Total other income expense net 0.67M 0.01M 0.02M 0.17M 0.15M
Discontinued operations - - - - -
Net income from continuing ops -9.92600M -19.32200M -9.73800M -5.48200M -7.93300M
Net income applicable to common shares -9.92600M -19.32200M -9.73800M -5.48200M -7.93300M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 37.86M 43.09M 54.92M 50.43M 8.54M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.16M 0.25M 1.06M 0.90M 0.12M
Total liab 0.84M 1.41M 3.88M 3.91M 0.93M
Total stockholder equity 37.02M 41.67M 51.04M 46.52M 7.61M
Deferred long term liab - - - - -
Other current liab 0.56M 0.80M 2.38M 1.73M 0.51M
Common stock 0.01M 0.01M 0.01M 0.01000M 0.00200M
Capital stock 0.01M 0.01M 0.01M 0.01000M 0.00200M
Retained earnings -188.74100M -183.40200M -173.47600M -154.15400M -144.41600M
Other liab - - - - -
Good will - - - - -
Other assets 0.00000M 0.02M 0.02M 0.44M 0.02M
Cash 37.43M 42.45M 53.36M 49.07M 8.36M
Cash and equivalents - - - - -
Total current liabilities 0.64M 1.13M 3.50M 3.50M 0.93M
Current deferred revenue -0.36200M - - - -
Net debt -37.15100M -42.16500M -52.97600M -48.66200M -8.36300M
Short term debt 0.08M - - 3.66M -
Short long term debt - - - - -
Short long term debt total 0.28M 0.28M 0.38M 0.41M -
Other stockholder equity 225.75M 225.06M 224.50M 200.66M 152.02M
Property plant equipment - 0.37M 0.48M 0.45M 0.01000M
Total current assets 37.59M 42.70M 54.42M 49.97M 8.48M
Long term investments - - - - -
Net tangible assets - 41.67M 51.04M 46.52M 7.61M
Short term investments - - - - -
Net receivables - - - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 0.36M 0.33M 1.12M 1.77M 0.42M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -0.36700M
Additional paid in capital - - - - -
Common stock total equity - - - 0.01000M 0.00200M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -154.15400M -144.41600M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.01M 0.02M 0.02M 0.01M 0.02M
Deferred long term asset charges - - - - -
Non current assets total 0.27M 0.39M 0.50M 0.46M 0.06M
Capital lease obligations 0.20M 0.28M 0.38M 0.41M -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.00200M -0.04300M -0.01900M -0.00400M 3.05M
Change to liabilities -0.78300M -0.41100M 1.10M 0.04M -1.29700M
Total cashflows from investing activities -0.00200M -0.04300M -0.01900M -0.00400M 3.05M
Net borrowings - - -0.40800M -0.34900M -0.31100M
Total cash from financing activities 0.00000M 23.09M 48.45M 6.56M 3.10M
Change to operating activities -0.87800M 0.38M 0.78M 0.25M -0.21600M
Net income -9.92600M -19.32200M -9.73800M -5.48200M -7.93300M
Change in cash -10.91400M 4.29M 40.71M 1.75M -2.09400M
Begin period cash flow 53.36M 49.07M 8.36M 6.61M 8.70M
End period cash flow 42.45M 53.36M 49.07M 8.36M 6.61M
Total cash from operating activities -10.91200M -18.76200M -7.72500M -4.80100M -8.24400M
Issuance of capital stock 0.00000M 24.07M 50.89M 7.28M 3.53M
Depreciation 0.11M 0.09M 0.09M 0.09M 0.02M
Other cashflows from investing activities - - - - 3.05M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - 48.86M 6.91M 3.42M
Other cashflows from financing activities -0.00200M -0.97700M -2.44200M -0.72100M -0.42800M
Change to netincome 0.56M 0.50M 0.04M 0.15M 0.27M
Capital expenditures 0.00200M 0.04M 0.02M 0.00400M 0.00400M
Change receivables - - - - -
Cash flows other operating - - -0.27500M 0.47M 0.69M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - 40.71M 1.75M -2.09400M
Change in working capital -1.66100M -0.02800M 1.88M 0.44M -0.60800M
Stock based compensation 0.56M 0.50M 0.04M 0.15M 0.27M
Other non cash items 0.00500M 19.35M -37.03800M -1.12900M 0.00200M
Free cash flow -10.91400M -18.80500M -7.74400M -4.80500M -8.24800M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
ABIO
ARCA Biopharma Inc		 - -% - - - - 1.27 -1.3579
NVO
Novo Nordisk A/S		 1.23 1.83% 68.25 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 3.60 5.42% 70.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.40 0.77% 444.06 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 10.20 1.71% 606.74 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

ARCA Biopharma Inc

10170 Church Ranch Way, Westminster, CO, United States, 80021

Key Executives

Name Title Year Born
Dr. Michael R. Bristow M.D., Ph.D. Co-Founder, Pres, CEO & Director 1945
Mr. Thomas A. Keuer Chief Operating Officer 1959
Mr. Christopher D. Ozeroff Sr. VP, Gen. Counsel & Sec. 1959
Mr. C. Jeffrey Dekker CPA Chief Financial Officer 1965
Dr. Michael R. Bristow M.D., Ph.D. Co-Founder, President, CEO & Director 1945
Mr. C. Jeffrey Dekker CPA CFO, Treasurer & Company Secretary 1965

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.